Maya Robin

Market Access Expert in Haematology @Novartis

Rueil-Malmaison, FR

Contributed to national pricing and reimbursement (P&R) strategy by drafting and coordinating multiple reimbursement dossiers (Note d\'Intérêt Thérapeutique (NIT), NIT Hospitalière, Note d\'Intérêt Economique), in collaboration with internal teams (medical, regulatory, HEOR.) and external stakeholders (consultants, KOL). → Prepared two standard reimbursement dossiers and one early access renewal application (AP2), ensuring alignment with regulatory expectations and timelines.Led a market access project for a key product, ensuring cross-functional alignment (with medical, regulatory, marketing. teams) and anticipating regulatory and strategic challenges.Participated in cross-functional projects including medico-economic discussions, pricing workshops on combotherapies, and strategic payer-medico boards.Created a practical guide on PMSI-based study implementation (MR-006), designed to assist Novartis market access teams in effectively carrying out these studies.Performed treatment cost calculations to support pricing strategy and demonstrate the economic value of therapies in health technology assessments.Creating a comprehensive One-Pager on medication pricing mechanisms in France, tailored for the global team to better understand the specificities of the French market. Conducted a thesis on the impact of safeguard clause mechanisms on the competitiveness of pharmaceutical companies specialized in innovative medicines in France.Developed a comprehensive understanding of the French access environment and its evolving regulatory landscape.